Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Couriel

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 20, 2003
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson, Ashwin Kashyap, Daniel Couriel, et al.
Transfusion Medicine Reviews|December 3, 2014
National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresisNora Ratcliffe, Nancy M Dunbar, Jill Adamski, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Leukemia & Lymphoma|October 26, 2011
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantQaiser Bashir, Mark F Munsell, Sergio Giralt, et al.
British Journal of Haematology|November 20, 2002
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood unitsMarcos De Lima, Lisa S St John, Eric D Wieder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2019
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple MyelomaAnita D'Souza, Parameswaran Hari, Marcelo Pasquini, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Blood|July 27, 2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemiaPartow Kebriaei, Michelle A Detry, Sergio Giralt, et al.
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 20, 2003
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefitBorje S Andersson, Ashwin Kashyap, Daniel Couriel, et al.
Transfusion Medicine Reviews|December 3, 2014
National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresisNora Ratcliffe, Nancy M Dunbar, Jill Adamski, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Leukemia & Lymphoma|October 26, 2011
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantQaiser Bashir, Mark F Munsell, Sergio Giralt, et al.
British Journal of Haematology|November 20, 2002
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood unitsMarcos De Lima, Lisa S St John, Eric D Wieder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 9, 2019
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple MyelomaAnita D'Souza, Parameswaran Hari, Marcelo Pasquini, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Pageof 8